Page last updated: 2024-11-08

roseoflavin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

roseoflavin: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

roseoflavin : A benzopteridine that is riboflavin in which the methyl group at position 8 is substituted by a dimethylamino group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID49867612
CHEBI ID72346
SCHEMBL ID863681
MeSH IDM0053677

Synonyms (13)

Synonym
roseoflavine
roseoflavin
1-deoxy-1-[8-(dimethylamino)-7-methyl-2,4-dioxo-3,4-dihydrobenzo[g]pteridin-10(2h)-yl]-d-ribitol
8-demethyl-8-(dimethylamino)riboflavin
CHEBI:72346
51093-55-1
SCHEMBL863681
Q27139923
C21647
8-(dimethylamino)-7-methyl-10-((2s,3s,4r)-2,3,4,5-tetrahydroxypentyl)benzo[g]pteridine-2,4(3h,10h)-dione
HY-121295
CS-0081382
AKOS040746299
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antimicrobial agentA substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
bacterial metaboliteAny prokaryotic metabolite produced during a metabolic reaction in bacteria.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
benzopteridine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (45)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (13.33)18.7374
1990's1 (2.22)18.2507
2000's8 (17.78)29.6817
2010's23 (51.11)24.3611
2020's7 (15.56)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (6.25%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other45 (93.75%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]